- TRADE NAME: Lorbrena (Pfizer)
- INDICATIONS:
indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on:
crizotinib and at least one other ALK inhibitor for metastatic disease;
or alectinib as the first ALK inhibitor therapy for metastatic disease;
or ceritinib as the first ALK inhibitor therapy for metastatic disease.
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor, Kinase inhibitor
- HALF-LIFE: 24 hours
- FDA APPROVAL DATE: 11/02/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Rifampin - PREGNANCY: can cause embryo-fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 04/30/2025
